share_log

bluebird bio | 4: Statement of changes in beneficial ownership of securities-Officer Colvin Richard A

bluebird bio | 4: Statement of changes in beneficial ownership of securities-Officer Colvin Richard A

bluebird bio | 4：持股变动声明-高管 Colvin Richard A
美股SEC公告 ·  10/02 16:12

Moomoo AI 已提取核心信息

On September 30, 2024, Richard A Colvin, the Chief Medical Officer of bluebird bio, Inc. [BLUE], completed a transaction acquiring 50,000 shares of the company's common stock at no cost. This grant of shares has increased Colvin's direct holdings in the company to a total of 168,368 shares. The transaction, which was a grant rather than a purchase on the open market, reflects the company's compensation or incentive strategy for its executives. The shares were granted directly to Colvin, emphasizing his vested interest in the company's performance.
On September 30, 2024, Richard A Colvin, the Chief Medical Officer of bluebird bio, Inc. [BLUE], completed a transaction acquiring 50,000 shares of the company's common stock at no cost. This grant of shares has increased Colvin's direct holdings in the company to a total of 168,368 shares. The transaction, which was a grant rather than a purchase on the open market, reflects the company's compensation or incentive strategy for its executives. The shares were granted directly to Colvin, emphasizing his vested interest in the company's performance.
2024年9月30日，蓝鸟生物公司（bluebird bio, Inc. [BLUE]）首席医疗官理查德·A·科尔文（Richard A Colvin）完成了一项交易，以零成本获得了该公司的50000股普通股。这次股份授予使科尔文在该公司的直接持股总数增至168,368股。这笔交易是一次授予，而不是在公开市场上购买，反映了公司对其高管的补偿或激励策略。这些股份直接授予科尔文，强调了他对公司表现的切身兴趣。
2024年9月30日，蓝鸟生物公司（bluebird bio, Inc. [BLUE]）首席医疗官理查德·A·科尔文（Richard A Colvin）完成了一项交易，以零成本获得了该公司的50000股普通股。这次股份授予使科尔文在该公司的直接持股总数增至168,368股。这笔交易是一次授予，而不是在公开市场上购买，反映了公司对其高管的补偿或激励策略。这些股份直接授予科尔文，强调了他对公司表现的切身兴趣。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间